Amneal Pharmaceuticals (AMRX) Operating Leases: 2018-2025
Historic Operating Leases for Amneal Pharmaceuticals (AMRX) over the last 7 years, with Sep 2025 value amounting to $26.4 million.
- Amneal Pharmaceuticals' Operating Leases rose 0.74% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year increase of 0.74%. This contributed to the annual value of $24.8 million for FY2024, which is 49.27% down from last year.
- Amneal Pharmaceuticals' Operating Leases amounted to $26.4 million in Q3 2025, which was down 4.41% from $27.6 million recorded in Q2 2025.
- Amneal Pharmaceuticals' 5-year Operating Leases high stood at $64.0 million for Q4 2021, and its period low was $22.9 million during Q1 2025.
- Moreover, its 3-year median value for Operating Leases was $26.8 million (2024), whereas its average is $28.7 million.
- In the last 5 years, Amneal Pharmaceuticals' Operating Leases grew by 6.83% in 2022 and then plummeted by 49.27% in 2024.
- Amneal Pharmaceuticals' Operating Leases (Quarterly) stood at $64.0 million in 2021, then decreased by 7.45% to $59.2 million in 2022, then declined by 17.42% to $48.9 million in 2023, then slumped by 49.27% to $24.8 million in 2024, then climbed by 0.74% to $26.4 million in 2025.
- Its Operating Leases was $26.4 million in Q3 2025, compared to $27.6 million in Q2 2025 and $22.9 million in Q1 2025.